½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

  • »¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

    021-54845833/15800441009

    Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

    µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ϸ°ûϵ > ÈËϸ°ûϵ > MDA-MB-231ÈËÈéÏÙ°©Ï¸°û(L15)

    ²úÆ·ÖÐÐÄ

    ×îвúÆ·

    • MDA-MB-231ÈËÈéÏÙ°©Ï¸°û(L15)

      ¹æ¸ñ£º
      ¼Û¸ñ£º£¤
      • Æ·ÅÆ : ͨεÉúÎï
      • Ŀ¼ºÅ : TW35330
      • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
      • »õÆÚ : ÏÖ»õ
      • ¹æ¸ñ £º1¡Á10?cells
    • ÉÌÆ·ÏêÇé
    • ²Î¿¼ÎÄÏ×
    • ˵Ã÷ÊéÏÂÔØ
    • ÉÌÆ·ÆÀÂÛ0
    • Ïà¹Ø²úÆ·
    »ù±¾ÐÅÏ¢
    ²úÆ·Æ·ÅÆ £ºÍ¨ÎµÉúÎï
    ÖÐÎÄÃû³Æ £ºÈËÈéÏÙ°©Ï¸°û(ÂÌɫӫ¹âµ°°×±ê¼Ç)
    ϸ°û¼ò³Æ £ºMDA-MB-231
    ϸ°û±ð³Æ £ºMDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231;MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA231; MB231;MD Anderson-Metastatic Breast-231
    ϸ°ûÐÎ̬ £ºÉÏÆ¤Ï¸°ûÑù
    Éú³¤ÌØÐÔ £ºÌù±Úϸ°û
    ÅàÑø»·¾³ £º¿ÕÆø£¬100% 37¡æ
    ¶³´æÌõ¼þ £º55% »ù´¡ÅàÑø»ù+40%FBS+5%DMSOÒºµª
    ÍêÈ«ÅàÑø»ù £ºLeibovitz's L-15(PM151010)£«10% FBS(164210-50)£«1% P/S(PB180120)

    ´«´ú²½Öè
    1¡¢Îü³öÔ­ÅàÑøÒº¡£
    2¡¢¼ÓÈë2ml×óÓÒPBS£¬ÇáÇá»Î¶¯ÅàÑøÆ¿Èóϴϸ°û,Îü³öPBS¶ªÆú¡£
    3¡¢¼ÓÈë1ml×óÓÒ0.25%Òȵ°°×øÈÜÒº£¨º¬EDTA£©£¬ÇáÇá»Î¶¯ÅàÑøÆ¿Ê¹Ö®½þÈóËùÓÐϸ°û¡£
    4¡¢·ÅÈëÅàÑøÏäÏû»¯£¬ÏÔ΢¾µÏ¿´µ½Ï¸°û¿éÖмäµÄϸ°ûÃ÷ÏÔ±äÔ²Óмä϶ʱ¿ÉÖÕÖ¹£¬È«³Ì²»ÒªÅÄ´òÅàÑøÆ¿¡£
    5¡¢¼ÓÈë3mlº¬ÑªÇåµÄÅàÑø»ùÖÕÖ¹Ïû»¯£¬´µ´òϸ°ûʹ֮Íѱڲ¢ÔÚÒºÌåÀï·´¸´´µ´òʹϸ°û¾¡Á¿³Êµ¥¿Åϸ°ûµÄÐü¸¡Òº¡£
    6¡¢ÊÕ¼¯Ï¸°ûÐüÒºÀëÐÄ£¬1200rpm/min 3·ÖÖÓ£¬ÀëÐÄÍêÎü³öÉÏÇ嶪Æú¡£
    7¡¢¼ÓÈëÐÂÏÊÅàÑø»ù£¬´µ´ò¼¸Ï»ìÔÈϸ°û¼´¿É£¬°´±ÈÀý½ÓÖÖµ½ÐÂÅàÑøÆ¿£¬²¹×ãÅàÑø»ù£¬Å¡ËÉÆ¿¸Ç»òʹÓÃÍ¸ÆøÆ¿¸Ç½øÐÐÅàÑø¡£
    Ïû»¯Ê±¼ä £º2-3min
    ´«´ú±ÈÀý£¨Ãܶȣ© £º1:2-1:4
    »»ÒºÆµ´Î £º2~3´Î/ÖÜ

    ϸ°û±³¾°ÃèÊö
    MDA-MB-231À´×Ô»¼ÓÐ×ªÒÆÈéÏÙÏÙ°©µÄ51ËêÅ®²¡È˵ÄÐØË®¡£ ÔÚÂãÊóºÍALS´¦ÀíµÄBALB/cСÊóÖУ¬ËüÄÜÐγɵͷֻ¯ÏÙ°©£¨III¼¶£©¡£Ï¸°û±í´ïWNT7B°©»ùÒò¡£
    ±¶Ôöʱ¼ä £º~32-42Сʱ
    ¹©ÌåÄêÁä £ºÅ®ÐÔ£¬51Ëê
    ×éÖ¯À´Ô´ £ºÈéÏÙÏÙ°©£¬×ªÒÆÐÔÐØÄ¤Éø³öÒº
    ϸ°ûÀàÐÍ £ºÖ×Áöϸ°û
    Ö×ÁöÀàÐÍ £ºÈéÏÙ°©Ï¸°û
    ÉúÎﰲȫµÈ¼¶ £º1
    ÖÂÁöÐÔ £ºYes, in ALS treated BALB/c mice, forms poorly differentiatedadenocarcinoma (grade III).Yes, in nude mice, forms poorly differentiatedadenocarcinoma (grade III)¡£
    ÊÜÌå±í´ï £ºepidermal growth factor (EGF), expressed;transforming growth factor alpha(TGF alpha), expressed
    ϸ°û±£²ØÖÐÐÄ £ºATCC; CRL-12532ATCC; HTB-26 ATCC; CRM-HTB-26 BCRC; 60425BCRJ; 0164 DSMZ; ACC-732 ECACC; 92020424

    ÊÕµ½³£ÎÂϸ°ûºóÈçºÎ´¦Àí
    ϸ°ûÅàÑøÏêϸ²Ù×÷²½ÖèÇë²ÎÕÕͨεÉúÎïϸ°ûÅàÑø²Ù×÷Ö¸ÄÏ
    1.ÊÕµ½³£ÎÂϸ°ûºó£¬¼°Ê±ÅÄÕռǼÓÐÎÞ©Һ/Æ¿ÉíÆÆËðÏÖÏó¡£
    2.ÓÃ75%¾Æ¾«²ÁÊÃϸ°ûÅàÑøÆ¿±íÃæ£¬ÏÔ΢¾µÏ¹۲ìϸ°û״̬¡£ÏȲ»Òª´ò¿ªÅàÑøÆ¿¸Ç£¬½«Ï¸°ûÖÃÓÚϸ°ûÅàÑøÏäÄÚ¾²ÖÃÅàÑø2-4Сʱ£¬ÒÔ±ãÎȶ¨Ï¸°û״̬¡£
    3.×ÐϸÔĶÁϸ°û˵Ã÷Ê飬Á˽âϸ°ûÏà¹ØÐÅÏ¢£¬ÈçÌù±ÚÌØÐÔ£¨Ìù±Ú/Ðü¸¡£©¡¢Ï¸°ûÐÎ̬¡¢ËùÓûù´¡ÅàÑø»ù¡¢ÑªÇå±ÈÀý¡¢ËùÐèϸ°ûÒò×Ó¡¢´«´ú±ÈÀý¡¢»»ÒºÆµÂʵÈ¡£
    4.¾²ÖÃÍê³Éºó£¬È¡³öϸ°ûÅàÑøÆ¿£¬¾µ¼ì¡¢ÅÄÕÕ£¬¼Ç¼ϸ°û״̬£¨ËùÅÄÕÕÆ¬ ½«×÷ΪºóÐø·þÎñÒÀ¾Ý£©£»½¨Òéϸ°û´«´úÅàÑøºó£¬¶¨ÆÚÅÄÕÕ¡¢¼Ç¼ϸ°ûÉú³¤×´Ì¬¡£
    5.Èô¹Û²ìµ½Òì³£»òÕß¶Ôϸ°ûÓÐÒÉÎÊ£¬Ç뼰ʱ¸úÎÒÃÇÁªÏµ£»¶ÔÓÚϸ°ûÅàÑø²Ù×÷¼°ÅàÑø¡£¿É¸úÎÒÃǵļ¼ÊõÖ§³Ö½»Á÷¡£

    ÊÛǰÐëÖª
    1¡¢¸Ãϸ°ûÍÆ¼öʹÓÃLeibovitz's L-15ÅàÑø»ù½øÐÐÅàÑø£¬Leibovitz's L-15²»¿ÉÒÔͨÈë¶þÑõ»¯Ì¼£¬»á²úÉúϸ°û¶¾ÐÔ¡£
    2¡¢ÈçÄúûÓÐÎÞ¶þÑõ»¯Ì¼µÄÅàÑøÏ䣬¿ÉʹÓÃDMEMÌæ´úLeibovitz's L-15£¬Ê¹ÓÃDMEMÅàÑø»ùʱ¼´¿ÉÕý³£Í¨Èë5%¶þÑõ»¯Ì¼¡£
    3¡¢ÅäÌ×רÓÃÅàÑø»ùĬÈÏLeibovitz's L-15ÅäÖã¬ÈçÐèDMEMÅä·½£¬ÇëÁªÏµÏúÊÛϵ¥±¸×¢¸ü¸Ä¡£
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿